PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 4:57 AM ET

Sponsor Check › Person

JM
No photo found yet (own website and image search run after this page is viewed)

John P. McKearn

Named as an officer, director or promoter on SEC Form D filings · CA, NC, TX, MO, WA · Mar 12, 2014 → Jul 23, 2021

17deals (issuers)
$1.07Breported sold
461investors
40Form D filings
2014–2021years on file
Follow this personLook further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:30 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

John P. McKearn is listed as an executive officer and director on 40 SEC Form D filings by 17 issuers between Sep 2010 and Apr 2026. Largest by amount reported sold: RiverVest Venture Fund V, L.P. (St. Louis, MO — pooled investment fund — 2020–2021; $275M reported sold to 96 investors), RiverVest Venture Fund IV, L.P. (St. Louis, MO — pooled investment fund — 2017–2018; $167.5M reported sold to 68 investors), Allotera Therapeutics, Inc. (St. Louis, MO — other health care — 2021; $123.3M reported sold to 27 investors), Allakos Inc. (San Carlos, CA — biotechnology — 2012–2017; $100.1M reported sold to 40 investors), RiverVest Venture Fund III, L.P. (St. Louis, MO — pooled investment fund — 2014–2015; $79.4M reported sold to 48 investors) and 12 more (all listed below).

What this means That is a lot of deals — 17 separate companies raised money with this person listed as executive officer and director, over about 16 years. Across those companies the filings report $1.07B sold in total.

Listed alongside Jay Schmelter (13 shared filings), Nicholas Walrod (9 shared filings), Niall O'Donnell (8 shared filings), John Mulligan (7 shared filings), Karl Handelsman (7 shared filings) and 109 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around John. Each name links to their own page.

The issuers belong to 2 sponsor groups: Rivervest Venture (7 issuers, $596.8M reported sold, 2014–2021) and Zacharon (2 issuers, $24.2M reported sold, 2010–2012).

What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 1 bankruptcy case matching the name listed in Key records below.

What this means 1 record came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

We compared 40 public filings for John P. McKearn and found 9 differences, 1 worth asking the sponsor about: 5 Form Ds were filed more than 15 days after the first sale; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for John P. McKearn has not run yet — it is joining a line of 2,597 names; searches run around the clock at the hosts' allowed rate. Searched so far: 27 names.

Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:30 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: AZ, CA, DE, TX, WA (crawled Oct 23, 2026)

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched John P. McKearn..

State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states are not covered.

3. Bankruptcies

1 case: 1 closed (disposition not in docket feed)

John McKearn and Dori McKearn closed
United States Bankruptcy Court, E.D. Wisconsin · No. 07-25229 · Filed Jul 9, 2007 · Closed Mar 27, 2009
Role of John McKearn and Dori McKearn: Debtor · Outcome: Case closed 2009-03-27 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same rare surname (3 people in Form D filings, 1 federal dockets); first name matches; court in WI (not a filing state); middle initial differs
What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:30 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

9 differences found between the filings for John P. McKearn — 1 worth asking about (compared 40 filings on Oct 24, 2026)

Worth asking · Dec 18, 2014 – Jul 23, 2021

5 Form Ds were filed more than 15 days after the first sale

Form D filed 466 days after the first sale — Allotera Therapeutics, Inc. · Form D filed 77 days after the first sale — Adarza BioSystems, Inc. · Form D filed 18 days after the first sale — Allakos Inc. · Form D filed 43 days after the first sale — Tioma Therapeutics, Inc. · Form D filed 56 days after the first sale — Tioma Therapeutics, Inc.

What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.

Form D · Jul 23, 2021 ↗Allotera Therapeutics, Inc. — PartnerFacts page ↗Form D · Feb 6, 2020 ↗Adarza BioSystems, Inc. — PartnerFacts page ↗
Sources
Note · Sep 3, 2010 – Mar 24, 2021

9 offerings changed their target amount between filings

Offering amount changed between filings — RiverVest Venture Fund V, L.P. · Offering amount changed between filings — Good Therapeutics, Inc. · Offering amount changed between filings — RiverVest Venture Fund IV, L.P. · Offering amount changed between filings — Tioma Therapeutics, Inc. · Offering amount changed between filings — Allakos Inc. · and 4 more

What this means Targets change as deals grow or shrink. Ask whether later money has the same terms.

Form D (earlier) · Oct 5, 2020 ↗Form D/A (later) · Mar 24, 2021 ↗RiverVest Venture Fund V, L.P. — PartnerFacts page ↗Form D (earlier) · Nov 21, 2018 ↗
Sources
Note · Aug 26, 2010 – May 6, 2025

16 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — OncoResponse, Inc (latest filing May 6, 2025) · No amendment in the last 12 months on an offering that may still be open — OncoResponse, Inc (latest filing May 12, 2023) · No amendment in the last 12 months on an offering that may still be open — Bonum Therapeutics, Inc. (latest filing Nov 29, 2022) · No amendment in the last 12 months on an offering that may still be open — Bonum Therapeutics, Inc. (latest filing Dec 22, 2021) · No amendment in the last 12 months on an offering that may still be open — Good Therapeutics, Inc. (latest filing Dec 22, 2021) · and 11 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Form D · May 6, 2025 ↗OncoResponse, Inc — PartnerFacts page ↗Form D · May 12, 2023 ↗Form D · Nov 29, 2022 ↗
Sources
Note · Sep 3, 2010 – Mar 12, 2014

John P. McKearn is written 2 different ways on the filings

listed as "John McKearn" on 25 filings (from Sep 3, 2010), and "John P. McKearn" on 15 filings (from Mar 12, 2014).

What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.

Form D · Sep 3, 2010 ↗Form D · Mar 12, 2014 ↗John P. McKearn — PartnerFacts page ↗
Sources
Note · Dec 20, 2012 – Dec 18, 2017

Industry group changed between filings — Allakos Inc.

"Pharmaceuticals" (Dec 20, 2012 to Mar 25, 2015); then "Biotechnology" (Dec 18, 2017).

What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.

Form D · Dec 20, 2012 ↗Form D · Dec 18, 2017 ↗Allakos Inc. — PartnerFacts page ↗
Sources
Note · May 24, 2012 – May 6, 2025

6 address changes between filings

Address moved from Seattle, WA to Houston, TX — OncoResponse, Inc · Address moved from Menlo Park, CA to Seattle, WA — OncoResponse, Inc · Address moved from Saint Louis, MO to Brisbane, CA — Tioma Therapeutics, Inc. · Address moved from San Mateo, CA to San Carlos, CA — Allakos Inc. · Address moved from Durham, NC to San Diego, CA — Lumena Pharmaceuticals, Inc. · and 1 more

What this means Businesses move. If you were told one city and the forms say another, ask which is current.

Form D · May 12, 2023 ↗Form D · May 6, 2025 ↗OncoResponse, Inc — PartnerFacts page ↗Form D · Sep 6, 2018 ↗
Sources
Note · Sep 3, 2010 – Apr 17, 2026

John P. McKearn is listed with 5 different address states: CA, NC, TX, MO, WA

CA on 8 filings (Sep 3, 2010 to Dec 18, 2017); NC on 2 filings (Feb 8, 2012 to May 24, 2012); TX on 3 filings (Oct 23, 2012 to May 6, 2025); MO on 20 filings (Mar 12, 2014 to May 12, 2023); WA on 7 filings (Nov 21, 2018 to Apr 17, 2026).

What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.

Form D · Sep 3, 2010 ↗Form D/A · Feb 8, 2012 ↗Form D · Oct 23, 2012 ↗Form D · Mar 12, 2014 ↗
Sources
Note · Aug 7, 2015 – Aug 17, 2016

Minimum investment changed between filings — Tioma Therapeutics, Inc.

The Aug 7, 2015 filing lists a minimum of $50,000; the Aug 17, 2016 Form D/A lists $0.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D (earlier) · Aug 7, 2015 ↗Form D/A (later) · Aug 17, 2016 ↗Tioma Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Mar 12, 2014 – Apr 13, 2015

Minimum investment changed between filings — RiverVest Venture Fund III, L.P.

The Mar 12, 2014 filing lists a minimum of $0; the Apr 13, 2015 Form D/A lists $125,000.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D (earlier) · Mar 12, 2014 ↗Form D/A (later) · Apr 13, 2015 ↗RiverVest Venture Fund III, L.P. — PartnerFacts page ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

1 of 28 offerings reports sales commissions totalling $1,656,000; 0 report finder's fees; 3 report proceeds to related persons totalling $7,400,000. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Apr 17, 2026 D
Bonum Therapeutics, Inc.
File 021-580902
$0$0$0None listed on this filingEDGAR ↗
May 6, 2025 D
OncoResponse, Inc
File 021-545368
$0$0$0None listed on this filingEDGAR ↗
May 12, 2023 D
OncoResponse, Inc
File 021-481584
$0$0$4,800,000 (est.)
The amount reflects payment of accrued and unpaid bonuses from periods prior to the offering and anticipated salary to the listed executive officers and potential bonus payments for the following 24-month period.
None listed on this filingEDGAR ↗
Nov 29, 2022 D
Bonum Therapeutics, Inc.
File 021-465970
$0$0$0None listed on this filingEDGAR ↗
Dec 22, 2021 D
Good Therapeutics, Inc.
File 021-426282
$0$0$0None listed on this filingEDGAR ↗
Dec 22, 2021 D
Bonum Therapeutics, Inc.
File 021-426281
$0$0$0None listed on this filingEDGAR ↗
Jul 23, 2021 D
Allotera Therapeutics, Inc.
File 021-407570
$0$0$0None listed on this filingEDGAR ↗
Jul 23, 2021 D
Allotera Therapeutics, Inc.
File 021-407610
$0$0$0None listed on this filingEDGAR ↗
Mar 31, 2021 D
OncoResponse, Inc
File 021-394093
$0$0$1,400,000 (est.)
The amount reflects payment of accrued and unpaid bonuses from periods prior to the offering and anticipated salary to the listed executive officers and potential bonus payments for the following 24-month period.
None listed on this filingEDGAR ↗
Mar 24, 2021 D/A
RiverVest Venture Fund V, L.P.
File 021-377132
$0$0$0 (est.)
The General Partner (or its designee) will receive a fee for management services payable by the Issuer quarterly in advance based on a percentage of aggregate subscriptions to the Issuer as specified in the Issuer's partnership agreement.
None listed on this filingEDGAR ↗
May 21, 2020 D/A
Good Therapeutics, Inc.
File 021-326349
$0$0$0None listed on this filingEDGAR ↗
Feb 6, 2020 D
Adarza BioSystems, Inc.
File 021-359887
$0$0$0None listed on this filingEDGAR ↗
Oct 9, 2018 D/A
RiverVest Venture Fund IV, L.P.
File 021-300811
$0$0$0 (est.)
The General Partner (or its designee) will receive a fee for management services payable by the Issuer quarterly in advance based on a percentage of aggregate subscriptions to the Issuer as specified in the Issuer's partnership agreement.
None listed on this filingEDGAR ↗
Sep 6, 2018 D
OncoResponse, Inc
File 021-320707
$0$0$1,200,000 (est.)
The amount reflects payments of accrued and unpaid bonuses from periods prior to the offering and anticipated salary to the listed executive officers and potential bonus payments for the following 24-month period.
None listed on this filingEDGAR ↗
Dec 18, 2017 D
Allakos Inc.
File 021-300963
$0$0$0None listed on this filingEDGAR ↗
Dec 22, 2016 D
3x5 RiverVest Fund II-B, L.P.
File 021-276937
$0$0$0 (est.)
Affiliates of the Managers of the Issuer's General Partner will receive a management fee payable by the Issuer quarterly in advance calculated in accordance with the Issuer's Amended and Restated Limited Partnership Agreement.
None listed on this filingEDGAR ↗
Dec 13, 2016 D
Archer Seed Fund, L.P.
File 021-276195
$0$0$0None listed on this filingEDGAR ↗
Nov 17, 2016 D/A
3x5 RiverVest Fund II, L.P.
File 021-251505
$0$0$0 (est.)
Affiliates of the Managers of the Issuer's General Partner will receive a management fee payable by the Issuer quarterly in advance calculated in accordance with the Issuer's Amended and Restated Limited Partnership Agreement.
None listed on this filingEDGAR ↗
Aug 17, 2016 D/A
Tioma Therapeutics, Inc.
File 021-245292
$0$0$0None listed on this filingEDGAR ↗
May 14, 2015 D/A
RiverVest Venture Fund III, L.P.
File 021-213378
$0$0$0 (est.)
The General Partner (or its designee) will receive a fee for management services payable by the Issuer quarterly in advance based on a percentage of aggregate subscriptions to the Issuer as specified in the Issuer's partnership agreement.
None listed on this filingEDGAR ↗
Mar 27, 2015 D
RiverVest Venture Fund III (Ohio), L.P.
File 021-236778
$0$0$0 (est.)
The General Partner (or its designee) will receive a fee for management services payable by the Issuer quarterly in advance based on a percentage of aggregate subscriptions to the Issuer as specified in the Issuer's partnership agreement.
None listed on this filingEDGAR ↗
Mar 25, 2015 D/A
Allakos Inc.
File 021-188692
$0$0$0None listed on this filingEDGAR ↗
Feb 12, 2015 D
Tioma Therapeutics, Inc.
File 021-233994
$0$0$0None listed on this filingEDGAR ↗
Mar 19, 2014 D
Lumena Pharmaceuticals, Inc.
File 021-213918
$0$0$0None listed on this filingEDGAR ↗
Mar 11, 2014 D
ZS Pharma, Inc.
File 021-213340
$0$0$0 (est.)None listed on this filingEDGAR ↗
Oct 23, 2012 D
ZS Pharma, Inc.
File 021-185980
$1,656,000$0$0 (est.)Salem Partners LLC BrokerCheck CRD 43363 ↗EDGAR ↗
May 24, 2012 D/A
Lumena Pharmaceuticals, Inc.
File 021-155528
$0$0$0None listed on this filingEDGAR ↗
Jun 2, 2011 D/A
Otonomy, Inc.
File 021-147275
$0$0$0None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 17

Every issuer that named John P. McKearn on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

BT
Biotechnology

Bonum Therapeutics, Inc.

Seattle, WA · Dec 22, 2021 → Apr 17, 2026 · 3 filings
  • Apr 17, 2026 · D · $26,907,396 sold of $32,301,381 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 29, 2022 · D · $45,041,421 sold of $93,041,420 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 22, 2021 · D · $1,186,887 sold of $3,560,661 · 5 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $45M from 10 investors (100% of the $32.3M target) as of the latest filing. John is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

O
Biotechnology

OncoResponse, Inc

Houston, TX · Sep 6, 2018 → May 6, 2025 · 4 filings
  • May 6, 2025 · D · $5,999,138 sold of Indefinite · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 12, 2023 · D · $13,915,153 sold of $40,000,000 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 31, 2021 · D · $40,625,995 sold of $60,000,000 · 14 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 6, 2018 · D · $18,999,999 sold of $39,999,995 · 12 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $40.6M from 14 investors as of the latest filing. John is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

GT
Biotechnology

Good Therapeutics, Inc.

Seattle, WA · Nov 21, 2018 → Dec 22, 2021 · 4 filings
  • Dec 22, 2021 · D · $8,813,099 sold of $26,439,316 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 21, 2020 · D/A · $22,335,003 sold of $22,335,003 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 8, 2019 · D/A · $11,185,002 sold of $22,335,003 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 21, 2018 · D · $6,035,002 sold of $18,035,006 · 3 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $22.3M from 6 investors (84% of the $26.4M target) as of the latest filing. John is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AT
Other Health Care

Allotera Therapeutics, Inc.

St. Louis, MO · Jul 23, 2021 → Jul 23, 2021 · 2 filings
  • Jul 23, 2021 · D · $98,500,011 sold of $172,000,014 · 27 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 23, 2021 · D · $37,233,405 sold of $37,233,405 · 6 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $123.3M from 27 investors (72% of the $172M target) as of the latest filing. John is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

RV
Pooled Investment Fund · group: Rivervest Venture

RiverVest Venture Fund V, L.P.

St. Louis, MO · Oct 5, 2020 → Mar 24, 2021 · 2 filings
  • Mar 24, 2021 · D/A · $275,000,000 sold of $275,000,000 · 96 investors · min. No minimum reported · role: Executive Officer (Manager of the GP LLC.) EDGAR ↗
  • Oct 5, 2020 · D · $0 sold of $200,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Manager of the GP LLC.) EDGAR ↗

Raised $275M from 96 investors (100% of the $275M target) as of the latest filing. John is listed as executive officer on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AB
Biotechnology

Adarza BioSystems, Inc.

St. Louis, MO · Feb 6, 2020
  • Feb 6, 2020 · D · $12,776,884 sold of $26,568,541 · 7 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $12.8M from 19 investors (48% of the $26.6M target) as of the latest filing. John is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

RV
Pooled Investment Fund · group: Rivervest Venture

RiverVest Venture Fund IV, L.P.

St. Louis, MO · Dec 14, 2017 → Oct 9, 2018 · 2 filings
  • Oct 9, 2018 · D/A · $167,525,000 sold of $167,525,000 · 68 investors · min. No minimum reported · role: Executive Officer (Manager of the general partner of the General Partner.) EDGAR ↗
  • Dec 14, 2017 · D · $0 sold of $150,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Manager of the general partner of the General Partner of the Issuer.) EDGAR ↗

Raised $167.5M from 68 investors (100% of the $167.5M target) as of the latest filing. John is listed as executive officer on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

A
Biotechnology

Allakos Inc.

San Carlos, CA · Dec 20, 2012 → Dec 18, 2017 · 4 filings
  • Dec 18, 2017 · D · $100,141,456 sold of $100,141,456 · 40 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 25, 2015 · D/A · $27,949,545 sold of $47,000,008 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 27, 2014 · D/A · $24,545,452 sold of $41,999,994 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 20, 2012 · D · $9,999,997 sold of $31,999,989 · 5 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $100.1M from 40 investors (100% of the $100.1M target) as of the latest filing. John is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

3R
Pooled Investment Fund · group: Rivervest Venture

3x5 RiverVest Fund II-B, L.P.

St. Louis, MO · Dec 22, 2016
  • Dec 22, 2016 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Executive Officer (Member of RiverVest 3x5 Managers II, LLC.) EDGAR ↗

No sales reported yet as of the latest filing. John is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AS
Pooled Investment Fund · group: Rivervest Venture

Archer Seed Fund, L.P.

St. Louis, MO · Dec 13, 2016
  • Dec 13, 2016 · D · $15,000,000 sold of $15,000,000 · 9 investors · min. $500,000 · role: Executive Officer (Member of the general partner of the General Partner of the Issuer.) EDGAR ↗

Raised $15M from 9 investors (100% of the $15M target) as of the latest filing. John is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

3R
Pooled Investment Fund · group: Rivervest Venture

3x5 RiverVest Fund II, L.P.

St. Louis, MO · Nov 18, 2015 → Nov 17, 2016 · 2 filings
  • Nov 17, 2016 · D/A · $55,850,000 sold of $125,000,000 · 54 investors · min. No minimum reported · role: Executive Officer (Member of RiverVest 3x5 Managers II, LLC.) EDGAR ↗
  • Nov 18, 2015 · D · $0 sold of $125,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Member of RiverVest 3x5 Managers II, LLC.) EDGAR ↗

Raised $55.9M from 54 investors (45% of the $125M target) as of the latest filing. John is listed as executive officer on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

TT
Pharmaceuticals

Tioma Therapeutics, Inc.

Brisbane, CA · Feb 12, 2015 → Aug 17, 2016 · 3 filings
  • Aug 17, 2016 · D/A · $33,176,948 sold of $86,253,438 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 7, 2015 · D · $8,134,451 sold of $45,000,000 · 10 investors · min. $50,000 · role: Director EDGAR ↗
  • Feb 12, 2015 · D · $1,269,350 sold of $2,768,250 · 3 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $33.2M from 12 investors (38% of the $86.3M target) as of the latest filing. John is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

RV
Pooled Investment Fund · group: Rivervest Venture

RiverVest Venture Fund III, L.P.

St. Louis, MO · Mar 12, 2014 → May 14, 2015 · 3 filings
  • May 14, 2015 · D/A · $79,425,000 sold of $150,000,000 · 48 investors · min. $125,000 · role: Executive Officer (Manager of the general partner of the General Partner of the Issuer.) EDGAR ↗
  • Apr 13, 2015 · D/A · $75,775,000 sold of $150,000,000 · 41 investors · min. $125,000 · role: Executive Officer (Manager of the general partner of the General Partner of the Issuer.) EDGAR ↗
  • Mar 12, 2014 · D · $0 sold of $150,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Manager of the general partner of the General Partner of the Issuer.) EDGAR ↗

Raised $79.4M from 48 investors (53% of the $150M target) as of the latest filing. John is listed as executive officer on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

RV
Pooled Investment Fund · group: Rivervest Venture

RiverVest Venture Fund III (Ohio), L.P.

Cleveland, OH · Mar 27, 2015
  • Mar 27, 2015 · D · $4,000,000 sold of $4,000,000 · 2 investors · min. $2,000,000 · role: Executive Officer (Manager of the General Partner of the Sole Member.) EDGAR ↗

Raised $4M from 2 investors (100% of the $4M target) as of the latest filing. John is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

LP
Pharmaceuticals

Lumena Pharmaceuticals, Inc.

San Diego, CA · Feb 8, 2012 → Mar 19, 2014 · 3 filings
  • Mar 19, 2014 · D · $45,499,993 sold of $45,499,993 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 24, 2012 · D/A · $2,550,150 sold of $2,550,150 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 8, 2012 · D/A · $2,550,000 sold of $2,550,000 · 6 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $45.5M from 13 investors (100% of the $45.5M target) as of the latest filing. John is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

ZP
Pharmaceuticals

ZS Pharma, Inc.

Coppell, TX · Oct 23, 2012 → Mar 11, 2014 · 2 filings
  • Mar 11, 2014 · D · $25,000,000 sold of $25,000,000 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 23, 2012 · D · $27,600,001 sold of $46,000,000 · 6 investors · min. $256,318 · role: Director EDGAR ↗

Raised $27.6M from 30 investors (100% of the $25M target) as of the latest filing. John is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

O
Biotechnology · group: Zacharon

Otonomy, Inc.

San Diego, CA · Sep 3, 2010 → Jun 2, 2011 · 2 filings
  • Jun 2, 2011 · D/A · $24,214,701 sold of $38,844,352 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 3, 2010 · D · $10,037,465 sold of $38,644,354 · 10 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $24.2M from 13 investors (62% of the $38.8M target) as of the latest filing. John is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

People around John 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

RV
Management entity

RiverVest Venture Partners III, L.P.

Director, Executive Officer · 4 shared filings (2 issuers)

Listed on the same filings as John P. McKearn. Their page shows their other deals.

3P
Management entity

3x5 Partners Managers II, L.P.

Executive Officer · 3 shared filings (2 issuers)

Listed on the same filings as John P. McKearn. Their page shows their other deals.

R3
Management entity

RiverVest 3x5 Managers II, L.P.

Executive Officer · 3 shared filings (2 issuers)

Listed on the same filings as John P. McKearn. Their page shows their other deals.

3R
Management entity

3x5 RiverVest Partners II, LLC

Director · 3 shared filings (2 issuers)

Listed on the same filings as John P. McKearn. Their page shows their other deals.

AS
Management entity

Archer Seed Partners, L.P.

Director · 1 shared filing (1 issuer)

Listed on the same filings as John P. McKearn. Their page shows their other deals.

JS
No photo found yet (own website and image search run after this page is viewed)
Person

Jay Schmelter

Executive Officer, Director · 13 shared filings (8 issuers) · also on 8 other issuers

Jay Schmelter is on 16 issuers in total — a repeat sponsor. Their page lists every one.

NW
No photo found yet (own website and image search run after this page is viewed)
Person

Nicholas Walrod

Executive Officer, Director · 9 shared filings (4 issuers) · also on 9 other issuers

Nicholas Walrod is on 13 issuers in total — a repeat sponsor. Their page lists every one.

ND
No photo found yet (own website and image search run after this page is viewed)
Person

Niall O'Donnell

Executive Officer · 8 shared filings (5 issuers) · also on 7 other issuers

Niall O'Donnell is on 12 issuers in total — a repeat sponsor. Their page lists every one.

TM
No photo found yet (own website and image search run after this page is viewed)
Person

Thomas C. Melzer

Executive Officer · 7 shared filings (4 issuers) · also on 1 other issuer

Thomas C. Melzer is on 5 issuers in total — a repeat sponsor. Their page lists every one.

JM
No photo found yet (own website and image search run after this page is viewed)
Person

John Mulligan

Executive Officer, Director, Promoter · 7 shared filings (2 issuers) · also on 1 other issuer

Listed on the same filings as John P. McKearn. Their page shows their other deals.

KH
No photo found yet (own website and image search run after this page is viewed)
Person

Karl Handelsman

Director · 7 shared filings (2 issuers)

Listed on the same filings as John P. McKearn. Their page shows their other deals.

RA
No photo found yet (own website and image search run after this page is viewed)
Person

Robert Alexander

Director, Executive Officer · 5 shared filings (3 issuers) · also on 3 other issuers

Robert Alexander is on 6 issuers in total — a repeat sponsor. Their page lists every one.

PM
No photo found yet (own website and image search run after this page is viewed)
Person

Peter Moldt

Director · 5 shared filings (2 issuers) · also on 9 other issuers

Peter Moldt is on 11 issuers in total — a repeat sponsor. Their page lists every one.

MM
No photo found yet (own website and image search run after this page is viewed)
Person

Mitchell Mutz

Director · 5 shared filings (2 issuers) · also on 4 other issuers

Mitchell Mutz is on 6 issuers in total — a repeat sponsor. Their page lists every one.

WH
No photo found yet (own website and image search run after this page is viewed)
Person

Wende Hutton

Director · 4 shared filings (1 issuer) · also on 17 other issuers

Wende Hutton is on 18 issuers in total — a repeat sponsor. Their page lists every one.

SG
No photo found yet (own website and image search run after this page is viewed)
Person

Steven Gillis

Director · 4 shared filings (1 issuer) · also on 29 other issuers

Steven Gillis is on 30 issuers in total — a repeat sponsor. Their page lists every one.

CS
No photo found yet (own website and image search run after this page is viewed)
Person

Clifford Stocks

Executive Officer, Director · 4 shared filings (1 issuer) · also on 5 other issuers

Clifford Stocks is on 6 issuers in total — a repeat sponsor. Their page lists every one.

DH
No photo found yet (own website and image search run after this page is viewed)
Person

Diane Hollenbaugh

Executive Officer · 4 shared filings (2 issuers) · also on 1 other issuer

Listed on the same filings as John P. McKearn. Their page shows their other deals.

MS
No photo found yet (own website and image search run after this page is viewed)
Person

Monique Schiersing

Director · 4 shared filings (2 issuers)

Listed on the same filings as John P. McKearn. Their page shows their other deals.

NP
No photo found yet (own website and image search run after this page is viewed)
Person

Neela Patel

Executive Officer · 4 shared filings (2 issuers)

Listed on the same filings as John P. McKearn. Their page shows their other deals.

MG
No photo found yet (own website and image search run after this page is viewed)
Person

Michael Grey

Executive Officer, Director · 3 shared filings (1 issuer) · also on 9 other issuers

Michael Grey is on 10 issuers in total — a repeat sponsor. Their page lists every one.

AA
No photo found yet (own website and image search run after this page is viewed)
Person

Anthony Arnerich

Executive Officer · 3 shared filings (2 issuers) · also on 12 other issuers

Anthony Arnerich is on 14 issuers in total — a repeat sponsor. Their page lists every one.

RK
No photo found yet (own website and image search run after this page is viewed)
Person

Robert W. Karr

Executive Officer, Director · 3 shared filings (1 issuer) · also on 4 other issuers

Robert W. Karr is on 5 issuers in total — a repeat sponsor. Their page lists every one.

NT
No photo found yet (own website and image search run after this page is viewed)
Person

Nenad Tomasevic

Executive Officer · 3 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as John P. McKearn. Their page shows their other deals.

CB
No photo found yet (own website and image search run after this page is viewed)
Person

Christopher Bebbington

Executive Officer, Director · 3 shared filings (1 issuer)

Listed on the same filings as John P. McKearn. Their page shows their other deals.

PM
No photo found yet (own website and image search run after this page is viewed)
Person

Pamela Manning

Executive Officer · 3 shared filings (1 issuer)

Listed on the same filings as John P. McKearn. Their page shows their other deals.

RD
No photo found yet (own website and image search run after this page is viewed)
Person

Roberto DePonti

Director · 3 shared filings (1 issuer)

Listed on the same filings as John P. McKearn. Their page shows their other deals.

KP
No photo found yet (own website and image search run after this page is viewed)
Person

Kamal D. Puri

Executive Officer · 3 shared filings (1 issuer)

Listed on the same filings as John P. McKearn. Their page shows their other deals.

PB
No photo found yet (own website and image search run after this page is viewed)
Person

Peter Bisgaard

Director · 2 shared filings (1 issuer) · also on 14 other issuers

Peter Bisgaard is on 15 issuers in total — a repeat sponsor. Their page lists every one.

BM
No photo found yet (own website and image search run after this page is viewed)
Person

Bali Muralidhar

Director · 2 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as John P. McKearn. Their page shows their other deals.

RT
No photo found yet (own website and image search run after this page is viewed)
Person

Robert B Truitt

Director · 2 shared filings (1 issuer) · also on 5 other issuers

Robert B Truitt is on 6 issuers in total — a repeat sponsor. Their page lists every one.

FC
No photo found yet (own website and image search run after this page is viewed)
Person

Farah Champsi

Director · 2 shared filings (1 issuer) · also on 6 other issuers

Farah Champsi is on 7 issuers in total — a repeat sponsor. Their page lists every one.

BD
No photo found yet (own website and image search run after this page is viewed)
Person

Brian H. Dovey

Director · 2 shared filings (1 issuer) · also on 14 other issuers

Brian H. Dovey is on 15 issuers in total — a repeat sponsor. Their page lists every one.

HP
No photo found yet (own website and image search run after this page is viewed)
Person

Heather Preston

Director · 2 shared filings (1 issuer) · also on 4 other issuers

Heather Preston is on 5 issuers in total — a repeat sponsor. Their page lists every one.

AG
No photo found yet (own website and image search run after this page is viewed)
Person

Alvaro Guillem

Executive Officer, Director · 2 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as John P. McKearn. Their page shows their other deals.

DK
No photo found yet (own website and image search run after this page is viewed)
Person

Donald Jeffrey Keyser

Executive Officer, Director · 2 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as John P. McKearn. Their page shows their other deals.

FW
No photo found yet (own website and image search run after this page is viewed)
Person

Ford S. Worthy

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as John P. McKearn. Their page shows their other deals.

The team behind the deals

RV
Sponsor group

Rivervest Venture

7 issuers · 12 filings · $596.8M reported sold · 2014–2021

One team, 7 deal companies. John P. McKearn is listed on 7 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name John P. McKearn.

Z
Sponsor group

Zacharon

2 issuers · 6 filings · $24.2M reported sold · 2010–2012

One team, 2 deal companies. John P. McKearn is listed on 1 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name John P. McKearn.

Same business address

45 other issuers file from the same address

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Adviser registration (Form ADV)

None of the 17 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to John P. McKearn by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 17 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers John P. McKearn is listed on: none on file. No website or social profile named in Allotera Therapeutics, Inc.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #16,638 of 374,652 in line (14 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (St. Louis, MO). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn people search ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗California — find the county court ↗Los Angeles Superior Court case search ↗North Carolina eCourts portal ↗Texas re:SearchTX court records ↗Missouri Case.net ↗Washington Courts case search (dw.courts.wa.gov) ↗Franklin County OH Clerk of Courts ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

California Secretary of State business search ↗North Carolina Secretary of State business search ↗Texas Secretary of State business search ↗Missouri Secretary of State business search ↗Washington Secretary of State business search ↗Ohio Secretary of State business search ↗OpenCorporates ↗

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when John P. McKearn appears on a new Form D, or when a court case or SEC action is matched to them. See plans →